Antiapoptotic Bcl-2 protein as a potential target for cancer therapy: A mini review

Hitesh Jagani; Narayanan Kasinathan; Sreenivasa Reddy Meka; Josyula Venkata Rao

doi:10.3109/21691401.2015.1019668

Antiapoptotic Bcl-2 protein as a potential target for cancer therapy: A mini review

Hitesh Jagani, Narayanan Kasinathan, Sreenivasa Reddy Meka, Josyula Venkata Rao^*

^*Corresponding author for this work

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal
Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal

Research output: Contribution to journal › Review article › peer-review

14 Citations (Scopus)

Abstract

Bcl-2, an antiapoptotic protein, is considered as a potential target in cancer treatment since its oncogenic potential has been proven and is well documented. Antisense technology and RNA interference (RNAi) have been used to reduce the expression of the Bcl-2 gene in many types of cancer cells and are effective as adjuvant therapy along with the chemotherapeutic agents. The lack of appropriate delivery systems is considered to be the main hurdle associated with the RNAi. In this review, we discuss the antiapoptotic Bcl-2 protein, its oncogenic potential, and various approaches utilized to target Bcl-2 including suitable delivery systems employed for successful delivery of siRNA.

Original language	English
Pages (from-to)	1212-1221
Number of pages	10
Journal	Artificial Cells, Nanomedicine and Biotechnology
Volume	44
Issue number	5
DOIs	https://doi.org/10.3109/21691401.2015.1019668
Publication status	Published - 03-07-2016

All Science Journal Classification (ASJC) codes

Biotechnology
Medicine (miscellaneous)
Biomedical Engineering
Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/21691401.2015.1019668

Cite this

@article{eefa812640924c2cbad2369f09aff595,

title = "Antiapoptotic Bcl-2 protein as a potential target for cancer therapy: A mini review",

abstract = "Bcl-2, an antiapoptotic protein, is considered as a potential target in cancer treatment since its oncogenic potential has been proven and is well documented. Antisense technology and RNA interference (RNAi) have been used to reduce the expression of the Bcl-2 gene in many types of cancer cells and are effective as adjuvant therapy along with the chemotherapeutic agents. The lack of appropriate delivery systems is considered to be the main hurdle associated with the RNAi. In this review, we discuss the antiapoptotic Bcl-2 protein, its oncogenic potential, and various approaches utilized to target Bcl-2 including suitable delivery systems employed for successful delivery of siRNA.",

author = "Hitesh Jagani and Narayanan Kasinathan and Meka, {Sreenivasa Reddy} and {Venkata Rao}, Josyula",

note = "Publisher Copyright: {\textcopyright} 2015 Informa Healthcare USA, Inc.",

year = "2016",

month = jul,

day = "3",

doi = "10.3109/21691401.2015.1019668",

language = "English",

volume = "44",

pages = "1212--1221",

journal = "Artificial Cells, Nanomedicine and Biotechnology",

issn = "2169-1401",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Antiapoptotic Bcl-2 protein as a potential target for cancer therapy

T2 - A mini review

AU - Jagani, Hitesh

AU - Kasinathan, Narayanan

AU - Meka, Sreenivasa Reddy

AU - Venkata Rao, Josyula

PY - 2016/7/3

Y1 - 2016/7/3

N2 - Bcl-2, an antiapoptotic protein, is considered as a potential target in cancer treatment since its oncogenic potential has been proven and is well documented. Antisense technology and RNA interference (RNAi) have been used to reduce the expression of the Bcl-2 gene in many types of cancer cells and are effective as adjuvant therapy along with the chemotherapeutic agents. The lack of appropriate delivery systems is considered to be the main hurdle associated with the RNAi. In this review, we discuss the antiapoptotic Bcl-2 protein, its oncogenic potential, and various approaches utilized to target Bcl-2 including suitable delivery systems employed for successful delivery of siRNA.

AB - Bcl-2, an antiapoptotic protein, is considered as a potential target in cancer treatment since its oncogenic potential has been proven and is well documented. Antisense technology and RNA interference (RNAi) have been used to reduce the expression of the Bcl-2 gene in many types of cancer cells and are effective as adjuvant therapy along with the chemotherapeutic agents. The lack of appropriate delivery systems is considered to be the main hurdle associated with the RNAi. In this review, we discuss the antiapoptotic Bcl-2 protein, its oncogenic potential, and various approaches utilized to target Bcl-2 including suitable delivery systems employed for successful delivery of siRNA.

UR - http://www.scopus.com/inward/record.url?scp=84976597114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976597114&partnerID=8YFLogxK

U2 - 10.3109/21691401.2015.1019668

DO - 10.3109/21691401.2015.1019668

M3 - Review article

C2 - 25801037

AN - SCOPUS:84976597114

SN - 2169-1401

VL - 44

SP - 1212

EP - 1221

JO - Artificial Cells, Nanomedicine and Biotechnology

JF - Artificial Cells, Nanomedicine and Biotechnology

IS - 5

ER -

Antiapoptotic Bcl-2 protein as a potential target for cancer therapy: A mini review

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this